Radium-223 therapy is a type of targeted alpha particle radiation therapy primarily used to treat prostate cancer that has metastasized to the bones. Radium-223 is a radioactive isotope that mimics calcium and selectively targets bone metastases. Radium-223 is administered to the patient via intravenous injection, typically given every four weeks for a total of six doses.
Learn about other professional services：
